Company intelligence / Profile preview

InterChina Partners

Ownership: Private
Employees: ~50
Development stage: Other

Overview

InterChina Partners is a leading independent corporate finance and M&A advisory firm specializing in China-related transactions. The firm provides strategic advice to multinational corporations, financial sponsors, and Chinese companies on mergers, acquisitions, divestments, restructurings, and financing. While it has significant experience advising clients in the healthcare and life sciences sectors—including pharmaceutical and biotech companies—InterChina itself is not a life science/biotech/pharma/healthcare company nor does it develop drugs or own clinical assets.

Industry: Consulting

Partnerships

Member of IMAP (International Mergers & Acquisitions Partnership), exclusive China partner since 2006

Beyond the preview

Go deeper on InterChina Partners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InterChina Partners.

Explore the full profile